Colorectal cancer is a malignant tumor that starts in the lining of the colon or rectum. Colorectal cancer is slow-growing, often taking years to develop.
Over 1.9 million new cases are diagnosed globally each year, and because early signs are subtle, many patients are already at an advanced stage when first detected. However, timely intervention can still open a window for curative outcomes — so seeking medical care as soon as possible is the single most important step you can take.
China reports approximately 550,000 new cases yearly—nearly 30% of the global burden. This extraordinary volume has forged unmatched expertise in two areas that matter most to patients: sphincter-preserving surgery for rectal cancer and world-class stoma care when a temporary or permanent ostomy is necessary. At Fosun Health, our colorectal teams perform thousands of complex low anterior resections, ultra-low rectal cancer operations, and multi-organ resections each year. "The more cases we see, the more precisely we protect your quality of life."
Every colorectal cancer program has surgery, drugs, and radiation. Here is what makes ours different:
"I have rectal cancer. Will I lose my anus and wear a colostomy bag for life? Will I be incontinent?"
The challenge: For rectal cancer patients, the deepest fear is often not death—it is losing the anus to a permanent stoma, or surviving with Low Anterior Resection Syndrome (LARS)—constant urgency, incomplete evacuation, and incontinence. When the tumor sits low in the rectum, many are told "you need a permanent colostomy." And if the tumor causes acute obstruction, emergency surgery often means a temporary or permanent stoma with no time to plan.
Our answer: Three integrated pathways to protect your bowel control and dignity:
Pathway A: Robotic Sphincter-Preserving Surgery The Da Vinci robot gives your surgeon 10× magnified 3D vision and tremor-free wristed instruments in the narrow, nerve-dense pelvic space. We perform Total Mesorectal Excision (TME) and Complete Mesocolic Excision (CME)with sub-millimeter precision, meticulously preserving the pelvic autonomic nerves that control bowel, urinary, and sexual function. Even for ultra-low rectal tumors—those closest to the anal verge—we maximize the chance of sphincter preservation, and dramatically reduce the risk of LARS.
Pathway B: Interventional Conversion When the tumor is too advanced for immediate sphincter preservation, our superselective transarterial infusion (via the inferior mesenteric artery, superior rectal artery, or internal iliac branches) delivers drug concentrations 50–100× higher than IV chemotherapy directly to the tumor. Combined with D-TACE, this shrinks bulky tumors significantly. After 1–3 sessions, many patients convert from "permanent stoma required" to "sphincter-preserving operation possible."
Pathway C: Emergency Stent-to-Surgery If acute malignant obstruction strikes, we place a self-expanding metal stent (SEMS)through the colonoscope to reopen the blocked bowel immediately—avoiding emergency colostomy. This buys time for full staging, neoadjuvant therapy, and a planned elective surgery with curative intent and maximal preservation.
What this means for you: A low-lying rectal tumor does not automatically mean a permanent stoma. Whether by robotic precision, interventional shrinkage, or emergency stent bridging—we fight to keep your natural bowel passage intact.
"My colorectal cancer has spread to my liver. Is this the end of the road?"
The challenge: Up to 50% of colorectal cancer patients develop liver metastases. The diagnosis feels like a death sentence. But in reality, liver metastases from colorectal cancer are among the most treatable metastases in all of oncology—if you have the right team and the right tools.
Our answer: A multi-modal liver-directed platform that treats every metastatic pattern:
- Image-Guided Ablation: For 1–3 small liver lesions, radiofrequency (RFA), microwave (MWA), or cryoablation destroys metastases through a needle puncture with millimeter accuracy—no large incision, no removal of healthy liver tissue. Combined with systemic therapy, this can achieve NED (No Evidence of Disease) status.
- Interventional Arterial Therapy: For multiple or larger liver metastases, TACE, D-TACE, or HAIC delivers high-concentration therapy directly into the hepatic artery feeding the tumors. Local drug concentrations reach 50–100× IV levels, while sparing the rest of the liver.
- CyberKnife Radiosurgery: For lesions in surgically risky locations—near major vessels or deep segments—0.1mm precision converges radiation from thousands of angles, ablating the metastasis while preserving surrounding liver function.
What this means for you: Liver metastases from colorectal cancer are not a terminal diagnosis—they are a treatable condition. Depending on the size, number, and location of your liver lesions, we can burn them, freeze them, starve them, or precision-radiate them—often in combination with systemic therapy to keep you disease-free for years.
"My cancer has returned in the pelvis, at the surgical connection, or in a lymph node. Do I need another major open surgery?"
The challenge: Local pelvic recurrence or isolated metastases to lymph nodes, lung, or bone threaten your treatment course and quality of life. Re-operative abdominal surgery carries high morbidity, longer recovery, and risks damaging surrounding bowel, bladder, and blood vessels. Many patients are simply not candidates.
Our answer: CyberKnife M6 delivers 0.1mm sub-millimeter stereotactic radiosurgery with real-time tracking. It converges radiation from thousands of angles to precisely ablate:
- Postoperative pelvic or anastomotic recurrences
- Regional lymph node relapses
- Bone or lung oligometastases
Because the procedure is completely non-invasive, there is no surgical trauma, no bleeding, no adhesion formation, and no interruption to your ongoing systemic therapy. The beam maximally spares the bladder, small bowel, and healthy colon.
What this means for you: A scan showing recurrence does not automatically mean another major operation. CyberKnife eliminates isolated recurrence sites in 1–5 outpatient sessions—while you remain on your chemotherapy or targeted therapy uninterrupted.
"I have progressed on FOLFOX and FOLFIRI. What comes next? And how can I afford years of treatment?"
The challenge: Metastatic colorectal cancer requires sequential lines of therapy. Resistance to oxaliplatin and irinotecan-based regimens is inevitable. When standard chemotherapy fails, the availability and cost of next-line agents determine whether you can continue fighting.
Our answer: In China, the next line comes sooner—and the comprehensive cost is 30%–50% of what you would pay in Europe or the US:
- MSI-H / dMMR tumors: PD-1 immunotherapy (pembrolizumab, nivolumab) delivers deep, durable remissions and is approved as first-line standard of care in China.
- RAS wild-type: Anti-EGFR monoclonal antibodies (cetuximab, panitumumab) remain highly effective when sequenced properly.
- BRAF V600E mutated: BRAF inhibitor combinations (encorafenib + cetuximab) provide a targeted alternative.
- HER2 amplified: Anti-HER2 regimens (trastuzumab + pertuzumab, or T-DXd) for previously treated disease.
- KRAS G12C mutated: KRAS G12C inhibitors already approved in China.
- China-original combinations: Novel protocols integrating anti-angiogenic TKIs with immunotherapy have shown superior outcomes and are endorsed by CSCO guidelines.
When all approved options are exhausted, our Phase III clinical trial fast-track provides access to next-generation agents 3–5 years ahead of availability elsewhere.
Guided by NGS profiling and physicians who have sequenced thousands of colorectal cases through multiple lines of resistance.
What this means for you: Your tumor's molecular profile—not guesswork—determines the next drug. And that drug is available here, at a cost that makes long-term, multi-line treatment financially sustainable.
Clinical Trial Fast-Track When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs parallel to your primary treatment as a "gut function and immunity optimizer":
Toxicity Reduction: Herbal formulations protect intestinal mucosa, regulate bowel movements, ease oxaliplatin-induced neuropathy and chemotherapy nausea, and reduce cancer-related fatigue. Specialized protocols address postoperative bowel dysfunction and stoma adaptation—critical for maintaining quality of life after rectal surgery.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to chemotherapy or targeted agents.
Acupuncture provides additional support for postoperative ileus, neuropathy, and fatigue. The goal: reduce treatment burden, restore normal bowel rhythm, and keep you strong enough to complete every planned cycle—on schedule.
Every colorectal cancer case is reviewed by a panel comprising colorectal surgery, hepatobiliary surgery (for liver metastases), interventional radiology, medical oncology, radiation oncology, radiology, and pathology specialists. Colorectal decisions are uniquely complex: sphincter preservation versus stoma, upfront surgery versus neoadjuvant therapy, liver metastasis resection versus ablation, and sequencing of systemic therapies through lines of resistance.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your cancer stage, your molecular profile, your organ function, and your priorities.
Diagnosis:
Stage IIIA Adenocarcinoma of the Sigmoid Colon, with tumor invasion through the muscularis propria into the pericolic adipose tissue, accompanied by limited hepatic metastasis and regional lymph node involvement.
Treatment Plan:
A multidisciplinary treatment strategy consisting of CyberKnife radiotherapy, curative surgical resection, and systemic adjuvant chemotherapy was implemented.
The patient initially underwent CyberKnife radiotherapy. Preoperative PET-CT demonstrated near-complete resolution of the hepatic metastatic lesion. Subsequently, laparoscopic sigmoid colectomy was performed successfully without intraoperative complications.
The patient was discharged on postoperative Day 5 and resumed normal daily activities within 3 weeks. Adjuvant systemic chemotherapy was continued for 6 months following surgery.
Given the elevated risk of recurrence associated with prior liver metastasis, an innovative dual-mechanism immunotherapeutic agent available in China was incorporated in addition to standard adjuvant chemotherapy. The objective was to further optimize the tumor immune microenvironment, reduce the risk of residual micrometastatic disease, and improve long-term disease-free survival.
Overall treatment was well tolerated. The patient experienced only mild fatigue, with no severe immune-related adverse events observed.
Outcome:
At the one-year follow-up, CT imaging demonstrated no evidence of recurrence or metastatic disease. The surgical anastomosis remained intact and well healed. Serum carcinoembryonic antigen (CEA) had normalized to 2.1 ng/mL.
The patient achieved clinical remission and returned to normal daily activities without functional limitations.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your complete medical documentation: Colonoscopy reports, pathology slides/reports, CT/MRI imaging, PET-CT scans, and NGS/genetic sequencing results. The Fosun Health Colorectal Cancer MDT Panel will conduct a comprehensive evaluation and deliver a personalized preliminary treatment plan within 48 hours.
